Harrow, Inc. (HROW)

Market Cap	1.51B
Revenue (ttm)	169.14M
Net Income (ttm)	-33.41M
Shares Out	35.61M
EPS (ttm)	-0.94
PE Ratio	n/a
Forward PE	180.60
Dividend	n/a
Ex-Dividend Date	n/a

Volume	572,951
Open	40.03
Previous Close	39.70
Day's Range	39.85 - 42.52
52-Week Range	8.72 - 59.23
Beta	0.76
Analysts	Strong Buy
Price Target	55.00 (+29.6%)
Earnings Date	Nov 13, 2024

About HROW

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic e...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 315
• Stock Exchange: NASDAQ
• Ticker Symbol: HROW
• Website: https://www.harrow.com

Financial Performance

In 2023, Harrow's revenue was $130.19 million, an increase of 46.95% compared to the previous year's $88.60 million. Losses were -$24.41 million, 73.3% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for HROW stock is "Strong Buy." The 12-month stock price forecast is $55.0, which is an increase of 29.60% from the latest price.

Price Target

$55.0

(29.60% upside)

Analyst Consensus: Strong Buy